Jade Biosciences, Inc. (NASDAQ:JBIO) Stock Rated "Moderate Buy" by Wall Street Brokerages

Jade Biosciences logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Analysts give Jade Biosciences a “Moderate Buy” consensus: Six of ten covering firms rate it Buy and two Strong Buy, with an average 12-month price target of $51.
  • The stock was down 5% and opened at $15.34. Jade reported a quarterly loss of $0.42 per share, narrower than analysts’ expected loss of $0.73.
  • Several institutional investors increased their holdings in the third quarter, including Bellevue Group, Pictet Asset Management, Goldman Sachs and Jump Financial.
  • MarketBeat previews top five stocks to own in December.

Jade Biosciences, Inc. (NASDAQ:JBIO - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten research firms that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, six have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $51.00.

A number of brokerages have recently issued reports on JBIO. Wedbush reissued an "outperform" rating and issued a $47.00 price target on shares of Jade Biosciences in a report on Thursday, October 1st. HC Wainwright reiterated a "buy" rating and set a $55.00 price target on shares of Jade Biosciences in a research report on Thursday, October 1st. Wall Street Zen upgraded shares of Jade Biosciences from a "strong sell" rating to a "sell" rating in a research report on Saturday. Guggenheim cut their target price on Jade Biosciences from $47.00 to $41.00 and set a "buy" rating for the company in a research note on Monday. Finally, Jefferies Financial Group reaffirmed a "buy" rating and set a $48.00 price objective on shares of Jade Biosciences in a research note on Tuesday, August 11th.

Get Our Latest Stock Analysis on JBIO

Jade Biosciences Stock Down 5.0%

Jade Biosciences stock opened at $15.34 on Friday. Jade Biosciences has a one year low of $10.98 and a one year high of $28.00. The business has a fifty day moving average price of $15.23 and a 200-day moving average price of $18.14.

Jade Biosciences (NASDAQ:JBIO - Get Free Report) last released its quarterly earnings data on Friday, November 13th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.73) by $0.31. On average, research analysts predict that Jade Biosciences will post -2.89 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of JBIO. Bellevue Group AG increased its stake in shares of Jade Biosciences by 40.4% during the third quarter. Bellevue Group AG now owns 4,293,937 shares of the company's stock valued at $60,330,000 after buying an additional 1,235,941 shares during the period. Janus Henderson Group PLC purchased a new position in shares of Jade Biosciences during the first quarter valued at approximately $43,557,000. Pictet Asset Management Holding SA raised its stake in Jade Biosciences by 64.4% during the third quarter. Pictet Asset Management Holding SA now owns 1,205,972 shares of the company's stock valued at $16,944,000 after buying an additional 472,204 shares during the last quarter. Goldman Sachs Group Inc. boosted its stake in Jade Biosciences by 22.0% in the 3rd quarter. Goldman Sachs Group Inc. now owns 896,834 shares of the company's stock worth $12,601,000 after purchasing an additional 161,610 shares in the last quarter. Finally, Jump Financial LLC lifted its stake in shares of Jade Biosciences by 75.3% in the third quarter. Jump Financial LLC now owns 302,812 shares of the company's stock worth $4,255,000 after buying an additional 130,065 shares in the last quarter.

About Jade Biosciences

(Get Free Report)

Jade Biosciences is a biotechnology company developing antibody-based treatments for autoimmune diseases. Its research focuses on targets involved in immune activity that can contribute to chronic disease. The company's lead program, JADE101, is an antibody designed to block APRIL, a protein involved in the production of antibodies. Jade is developing the candidate for IgA nephropathy, a kidney disease in which abnormal IgA antibodies can damage the kidneys. Jade's pipeline is focused on potential therapies for autoimmune conditions.

Recommended Stories

Analyst Recommendations for Jade Biosciences (NASDAQ:JBIO)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Jade Biosciences Right Now?

Before you consider Jade Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Jade Biosciences wasn't on the list.

While Jade Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Stocks to Own in Fall 2026 Cover

AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines